<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642538</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-253-002</org_study_id>
    <secondary_id>EudraCT #: 2007-003430-42</secondary_id>
    <nct_id>NCT00642538</nct_id>
  </id_info>
  <brief_title>A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <brief_summary>
    <textblock>
      20 eligible subjects will be enrolled into the treatment phase of the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial objectives are to determine the safety &amp; pharmacological response of MKC253 Inhalation
      Powder.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-240 min post-prandial serum glucose</measure>
    <time_frame>240 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg dose of GLP-1 as MKC253 Inhalation Powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg dose of GLP-1 as MKC253 Inhalation Powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg dose of GLP-1 as MKC253 Inhalation Powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TIP (placebo comparison)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 ug subcutaneous control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC253 Inhalation Powder</intervention_name>
    <description>Inhalation Powder, prandial</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere Inhalation Powder</intervention_name>
    <description>Inhalation Powder, prandial</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous injection</intervention_name>
    <description>10Âµg Exenatide, prandial</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking males and females between 18 and 70 years of age

          -  Body Mass Index (BMI) of &lt; 32 kg/m2

          -  Diabetes managed on a stable regimen of diet and exercise within the preceding 8 weeks
             and/or metformin and/or a sulfonylurea or meglitinide or alpha glucosidase inhibitors,
             without any dose adjustments within the preceding 8 weeks. For subjects taking both
             metformin and sulfonylurea or meglitinide or alpha glucosidase inhibitor, one or both
             oral agents must be less than 1/2 the maximal allowable dose as cited in the product
             label.

          -  HbA1c = 6.2 to = 8.5%. Fasting C-peptide = 0.5 ng/mL. On the last 3 days of the
             washout period (Day -3, -2, and -1) subjects should have a FBG (finger stick) = 13.5
             mmol/L.

          -  Normal pulmonary function and performance on pulmonary function tests

          -  Written Informed Consent

          -  Treatment with any type of anti-diabetic therapy other than metformin, sulfonylurea,
             meglitinide and alpha glucosidase inhibitors within the preceding 12 weeks [ie,
             thiazolidinediones (TZDs), dipeptyl peptidase inhibitors (DPP-IV), Symlin (pramlintide
             acetate) and or Byetta (exenatide)].

        Exclusion Criteria:

          -  Exposure to any investigational medications or devices within the previous 90 days
             prior to trial entry or participation in another clinical trial while participating in
             this trial.

          -  Use of any prescription medication within 90 days prior to screening, other than
             allowed anti-diabetic therapy, that has not been approved by the PI and Sponsor. The
             use of alpha blockers, antihypertensives, proton pump inhibitors and cholesterol
             medication as co-medications is allowed throughout the study.

          -  Significant improvement in pre- to post-bronchodilator spirometry (defined as an
             increase of 12% AND 200 mL in either FVC OR FEV1).

          -  Serum creatinine above Upper Limit of Normal (ULN) as defined by the laboratory

          -  Any other condition which, in the opinion of the PI, makes the subject unsuitable for
             the clinical trial, or could limit the validity of the informed consent and/or impair
             the subject's ability to participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Boss</last_name>
    <role>Study Director</role>
    <affiliation>Mannkind Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9470 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic adult male, diabetic postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

